Clidinium

Identification

Summary

Clidinium is a synthetic anticholinergic used to treat peptic ulcer disease, colicky abdominal pain, diverticulitis, and IBS.

Brand Names
Chlorax, Librax
Generic Name
Clidinium
DrugBank Accession Number
DB00771
Background

Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 352.4467
Monoisotopic: 352.191268703
Chemical Formula
C22H26NO3
Synonyms
  • 3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane
  • 3-hydroxy-1-methylquinuclidinium benzilate ester
  • Bromure de Clidinium
  • Bromuro de clidinio
  • Clidinii Bromidum
  • Clidinium bromid
  • N-methyl quinuclidinyl benzilate

Pharmacology

Indication

For the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.

Mechanism of action

Inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites primarily by inhibiting the M1 muscarinic receptors.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Signs of toxicity include confusion, paralytic ileus, urinary hesitancy/retention, and blurred vision.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-Benzodiazepine1,2-Benzodiazepine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
AcetazolamideAcetazolamide may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
AcetophenazineAcetophenazine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
AclidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Clidinium.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Clidinium is combined with Alfentanil.
AlimemazineAlimemazine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Clidinium.
AlmotriptanAlmotriptan may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Avoid alcohol. Ingesting alcohol may increase the CNS depressant effects of the combination product Chlordiazepoxide HCl and Clidinium Bromide.
  • Take before a meal.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Clidinium Bromide91ZQW5JF1Z3485-62-9GKEGFOKQMZHVOW-UHFFFAOYSA-M
Product Images
International/Other Brands
Dolibrax (Roche) / Porsucon (Ying Yuan) / Quarzan (Roche) / Sedaspa (Hua Shin)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
APO-CHLORAX CAPSULEClidinium Bromide (2.5 mg) + Chlordiazepoxide hydrochloride (5 mg)CapsuleOralPHARMAFORTE SINGAPORE PTE LTD1989-06-07Not applicable
CHLOBAX TABLETClidinium Bromide (2.5 mg) + Chlordiazepoxide (5 mg)Tablet, sugar coatedOralBEACONS PHARMACEUTICALS PTE. LTD.1996-04-19Not applicable
ChloraxClidinium Bromide (2.5 mg) + Chlordiazepoxide hydrochloride (5 mg)CapsuleOralAa Pharma Inc1984-12-31Not applicableCanada flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralCameron Pharmaceuticals, LLC1966-09-01Not applicableUS flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralbryant ranch prepack2020-07-09Not applicableUS flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralDr. Reddy's Laboratories Inc.2021-05-10Not applicableUS flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralAvera McKennan Hospital2016-01-18Not applicableUS flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralSunrise Pharmaceutical, Inc.2020-07-09Not applicableUS flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 1/1) + Chlordiazepoxide (5 mg/1)CapsuleOralXiromed, Llc2021-04-05Not applicableUS flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralOceanside Pharmaceuticals2009-09-232019-02-28US flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Chlordiazepoxide ClidiniumClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralRiver's Edge Pharmaceuticals, LLC2009-06-022012-03-31US flag
CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDEClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralAscend Laboratories, LLC2010-01-222012-12-30US flag
CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDEClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralGolden State Medical Supply2010-01-222012-03-30US flag
Chlordiazepoxide Hydrochloride And Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralAcella Pharmaceuticals, LLC2011-05-262015-03-31US flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralBi-Coastal Pharmaceutical Corporation2011-05-04Not applicableUS flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralPhysicians Total Care, Inc.1996-06-202013-01-15US flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralMacoven Pharmaceuticals2011-05-042015-06-04US flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralBreckenridge Pharmaceutical, Inc.2009-02-012011-02-28US flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralAv Kare, Inc.2013-01-032013-11-04US flag
Chlordiazepoxide Hydrochloride and Clidinium BromideClidinium Bromide (2.5 mg/1) + Chlordiazepoxide hydrochloride (5 mg/1)CapsuleOralBurel Pharmaceuticals, Llc2016-04-152017-03-24US flag

Categories

ATC Codes
A03CA02 — Clidinium and psycholeptics
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Quinuclidines / Piperidines / Tetraalkylammonium salts / Tertiary alcohols / Carboxylic acid esters / Monocarboxylic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic salts / Organic oxides
show 5 more
Substituents
Alcohol / Amine / Aromatic alcohol / Aromatic heteropolycyclic compound / Azacycle / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Diphenylmethane / Hydrocarbon derivative
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
carboxylic ester, organic cation, quaternary ammonium ion (CHEBI:3743)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
BO76JF850N
CAS number
7020-55-5
InChI Key
HOOSGZJRQIVJSZ-NNBUQUNQSA-N
InChI
InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1/t17-,20?,23+
IUPAC Name
(1s,4s)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1-methyl-1-azabicyclo[2.2.2]octan-1-ium
SMILES
C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1

References

Synthesis Reference

Sternbach, L.H.; US. Patent 2,648,667; August 11,1953; assigned to Hoffmann-LaRoche, Inc.

General References
Not Available
Human Metabolome Database
HMDB0014909
KEGG Compound
C07853
PubChem Compound
2784
PubChem Substance
46507814
ChemSpider
26330531
BindingDB
50055977
RxNav
21232
ChEBI
3743
Therapeutic Targets Database
DAP001117
PharmGKB
PA164781044
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Clidinium_bromide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableUnknown StatusTreatmentChest Pain1

Pharmacoeconomics

Manufacturers
  • Hoffmann la roche inc
Packagers
  • Avkare Incorporated
  • Boca Pharmacal
  • Breckenridge Pharmaceuticals
  • Bryant Ranch Prepack
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Excellium Pharmaceutical Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • KVK-Tech Inc.
  • Legacy Pharmaceuticals Packaging LLC
  • Macoven Pharmaceuticals LLC
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • Oceanside Pharmaceuticals Incorporated
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Provident Pharmaceuticals LLC
  • Resource Optimization and Innovation LLC
  • River's Edge Pharmaceuticals
  • Southwood Pharmaceuticals
  • Veratex Corp.
Dosage Forms
FormRouteStrength
CapsuleOral5 mg
Tablet, sugar coatedOral5 mg
CapsuleOral
Capsule, gelatin coatedOral
Tablet, film coatedOral
Tablet, coatedOral
PillOral
Tablet, sugar coatedOral
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Quarzan 5 mg capsule0.3USD capsule
Quarzan 2.5 mg capsule0.23USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)240-241 °CSternbach, L.H.; US. Patent 2,648,667; August 11,1953; assigned to Hoffmann-LaRoche, Inc.
Predicted Properties
PropertyValueSource
Water Solubility0.000377 mg/mLALOGPS
logP-0.5ALOGPS
logP-1.1ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)11.05ChemAxon
pKa (Strongest Basic)-4.5ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity112.14 m3·mol-1ChemAxon
Polarizability38.76 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9243
Blood Brain Barrier+0.9142
Caco-2 permeable+0.671
P-glycoprotein substrateSubstrate0.8526
P-glycoprotein inhibitor INon-inhibitor0.7661
P-glycoprotein inhibitor IINon-inhibitor0.9576
Renal organic cation transporterInhibitor0.6314
CYP450 2C9 substrateNon-substrate0.7781
CYP450 2D6 substrateNon-substrate0.6956
CYP450 3A4 substrateSubstrate0.6095
CYP450 1A2 substrateNon-inhibitor0.9528
CYP450 2C9 inhibitorNon-inhibitor0.9459
CYP450 2D6 inhibitorInhibitor0.6154
CYP450 2C19 inhibitorNon-inhibitor0.9577
CYP450 3A4 inhibitorNon-inhibitor0.9504
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9889
Ames testNon AMES toxic0.8557
CarcinogenicityNon-carcinogens0.933
BiodegradationReady biodegradable0.7763
Rat acute toxicity2.4948 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8162
hERG inhibition (predictor II)Non-inhibitor0.6539
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Drug created on June 13, 2005 13:24 / Updated on May 06, 2021 01:40